Cargando…

Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study

This study aimed to investigate the therapeutic effect of cataract surgery along with simultaneous intravitreal injection (IVI) of aflibercept on diabetic macular edema (DME). This cohort study enrolled 106 patients aged >40 years with type 2 diabetes mellitus and DME who received cataract surger...

Descripción completa

Detalles Bibliográficos
Autores principales: Yen, Chu-Yu, Yen, Ju-Chuan, Chen, Chun-Chen, Hu, Hsiao-Yun, Cheng, Feng-Shiang, Tseng, Po-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387960/
https://www.ncbi.nlm.nih.gov/pubmed/35984152
http://dx.doi.org/10.1097/MD.0000000000030115
_version_ 1784770117306941440
author Yen, Chu-Yu
Yen, Ju-Chuan
Chen, Chun-Chen
Hu, Hsiao-Yun
Cheng, Feng-Shiang
Tseng, Po-Chen
author_facet Yen, Chu-Yu
Yen, Ju-Chuan
Chen, Chun-Chen
Hu, Hsiao-Yun
Cheng, Feng-Shiang
Tseng, Po-Chen
author_sort Yen, Chu-Yu
collection PubMed
description This study aimed to investigate the therapeutic effect of cataract surgery along with simultaneous intravitreal injection (IVI) of aflibercept on diabetic macular edema (DME). This cohort study enrolled 106 patients aged >40 years with type 2 diabetes mellitus and DME who received cataract surgery from January 1, 2016, to October 31, 2020. The baseline and mean data of the following parameters were collected: age, sex, glycated hemoglobin level, diabetic retinopathy (DR) grading, previous DR treatments including IVI of anti–vascular endothelial growth factor and pan-retinal photocoagulation, intraocular pressure, use of intraocular pressure-lowering medication, central subfield thickness (CST), and log MAR visual acuity (VA). Patients were categorized into 2 groups based on whether they received aflibercept IVI or not during cataract surgery and were compared using the t test and Fisher exact test for continuous and discrete variables, respectively. Beta coefficient and standard error were calculated using multiple linear regression analysis to identify the explanatory variables predictive of the net change of CST and log MAR VA. There was no difference in the net change in CST (15.24 ± 45.07 μm vs 18.62 ± 33.84 μm, P = .772) and log MAR VA (−0.27 ± 0.29 vs −0.37 ± 0.31, P = .215). Gender, glycated hemoglobin level, aflibercept IVI during cataract surgery, and baseline CST did not interfere with the morphological and functional outcomes of DME in cataract surgery. Older age was significantly and independently associated with a greater net change in log MAR VA. Proliferative DR was significantly and independently associated with a greater net change in CST and log MAR VA. A greater baseline log MAR VA was significantly and independently associated with lower net change in log MAR VA. Simultaneous aflibercept IVI for treating DME may not interfere with the functional and tomographic parameters of cataract surgery relative to cataract surgery alone. Factors influencing the outcomes of patients with DME undergoing cataract surgery are as follows: age, baseline DR staging, and baseline VA. Identifying these factors of DME preoperatively may be an important consideration in preventing it from progressing and for improving the overall visual prognosis.
format Online
Article
Text
id pubmed-9387960
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-93879602022-08-23 Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study Yen, Chu-Yu Yen, Ju-Chuan Chen, Chun-Chen Hu, Hsiao-Yun Cheng, Feng-Shiang Tseng, Po-Chen Medicine (Baltimore) Research Article This study aimed to investigate the therapeutic effect of cataract surgery along with simultaneous intravitreal injection (IVI) of aflibercept on diabetic macular edema (DME). This cohort study enrolled 106 patients aged >40 years with type 2 diabetes mellitus and DME who received cataract surgery from January 1, 2016, to October 31, 2020. The baseline and mean data of the following parameters were collected: age, sex, glycated hemoglobin level, diabetic retinopathy (DR) grading, previous DR treatments including IVI of anti–vascular endothelial growth factor and pan-retinal photocoagulation, intraocular pressure, use of intraocular pressure-lowering medication, central subfield thickness (CST), and log MAR visual acuity (VA). Patients were categorized into 2 groups based on whether they received aflibercept IVI or not during cataract surgery and were compared using the t test and Fisher exact test for continuous and discrete variables, respectively. Beta coefficient and standard error were calculated using multiple linear regression analysis to identify the explanatory variables predictive of the net change of CST and log MAR VA. There was no difference in the net change in CST (15.24 ± 45.07 μm vs 18.62 ± 33.84 μm, P = .772) and log MAR VA (−0.27 ± 0.29 vs −0.37 ± 0.31, P = .215). Gender, glycated hemoglobin level, aflibercept IVI during cataract surgery, and baseline CST did not interfere with the morphological and functional outcomes of DME in cataract surgery. Older age was significantly and independently associated with a greater net change in log MAR VA. Proliferative DR was significantly and independently associated with a greater net change in CST and log MAR VA. A greater baseline log MAR VA was significantly and independently associated with lower net change in log MAR VA. Simultaneous aflibercept IVI for treating DME may not interfere with the functional and tomographic parameters of cataract surgery relative to cataract surgery alone. Factors influencing the outcomes of patients with DME undergoing cataract surgery are as follows: age, baseline DR staging, and baseline VA. Identifying these factors of DME preoperatively may be an important consideration in preventing it from progressing and for improving the overall visual prognosis. Lippincott Williams & Wilkins 2022-08-19 /pmc/articles/PMC9387960/ /pubmed/35984152 http://dx.doi.org/10.1097/MD.0000000000030115 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle Research Article
Yen, Chu-Yu
Yen, Ju-Chuan
Chen, Chun-Chen
Hu, Hsiao-Yun
Cheng, Feng-Shiang
Tseng, Po-Chen
Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study
title Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study
title_full Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study
title_fullStr Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study
title_full_unstemmed Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study
title_short Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study
title_sort therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: an observational study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387960/
https://www.ncbi.nlm.nih.gov/pubmed/35984152
http://dx.doi.org/10.1097/MD.0000000000030115
work_keys_str_mv AT yenchuyu therapeuticeffectofcataractsurgerywithsimultaneousintravitrealinjectionofafliberceptondiabeticmacularedemaanobservationalstudy
AT yenjuchuan therapeuticeffectofcataractsurgerywithsimultaneousintravitrealinjectionofafliberceptondiabeticmacularedemaanobservationalstudy
AT chenchunchen therapeuticeffectofcataractsurgerywithsimultaneousintravitrealinjectionofafliberceptondiabeticmacularedemaanobservationalstudy
AT huhsiaoyun therapeuticeffectofcataractsurgerywithsimultaneousintravitrealinjectionofafliberceptondiabeticmacularedemaanobservationalstudy
AT chengfengshiang therapeuticeffectofcataractsurgerywithsimultaneousintravitrealinjectionofafliberceptondiabeticmacularedemaanobservationalstudy
AT tsengpochen therapeuticeffectofcataractsurgerywithsimultaneousintravitrealinjectionofafliberceptondiabeticmacularedemaanobservationalstudy